Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hopefully this may see some positive action...
https://www.dailymail.co.uk/money/investing/article-10153021/SMALL-CAP-SHARE-IDEAS-Creo-Medical-eyes-acquisitions.html
Looked at from a more positive angle: first half organic sales have gone from zero to £0.1m, with more to come in the second half and on an ongoing basis. The purchase of Albyn has been immediately successful. Further fundraising is always a possibility to fuel growth, but with revenue visibly increasing, both organically AND from acquisitions (it all counts!) the need for it is surely diminishing.
I’m still struggling here, £0.1m of organic product sales.
Only revenue is from a business they bought.
Looks like a lot of more equity is needed from us to pay for their continued attempts at growth.
Actually, Gareth Walsh only worked for the company Mar 2019 - Aug 2020 so is long gone. Seems like a very strange reason for reaching your grim conclusion anyway - surely more instructive to look at the company's products and early revenue trajectory?
Gareth Walsh, the ex Olympus Director works for them. I can tell you now that this company is doomed.
Afternoon Red. Reading back thru RNSs it looks like this is the third? Jul 18 £48.5m @ 125p, Dec 19 £56.6m@ 180p, Aug 21 £35m @ 182.5p (approx, including open offers).
Quite a lot of purposes for the money, including clinical trials in China and Japan, which shows the company's scope of ambition. They did generate some revenue last year - just £9.43m, but it's a start - hopefully this funding round will lean into a period of rapid expansion in revenue as well as product development and deployment.
Yet another share raise. Every new doctor paid for by shareholders.... makes it rather hard for any capital appreciation if costs are consistently being funded by us at least we could get some forecasts if they want to keep using equity
Yes, terrific news about a successful use of the device when other options were unusable - very very good news, for the patient and for the inventors - looks like a winner.
Welcome Brava2021, I think your timing is good here because revenue is starting to flow after a long period of outflows for R&D, regulatory hurdles and sales force building. Looks very promising post-pandemic - good luck!
hopefully with this RNs it is a GOOD future
Just bought some of these shares.....wanted to say hi to the group!
More good news as the financial number crunchers at the NHS get to work. They rule.
Business panning out even better than expected, continuing the momentum from the terrific February trading update. Price has drifted down since then, but all the indications are that this business has gained serious traction and the revenue tap has started flowing strongly.
What a great RNS - finally showing the results and revenues from all the years of hard work. Congratulations. Onwards and upwards.
Rim very concerned about you MORWENATRELAWNE: long awkward silence - U OK? Did you take some of those magic pills?
Anonymous Canadians dumped 1% of the shares today, but things are looking good here, imo, with revenue starting to flow.
Just heard? BBC were reporting on that before CREO even existed:
http://news.bbc.co.uk/1/hi/england/2148973.stm
Nice first post MORWENATRELAWNE, welcome to the board. Who is Rim, and what are they so concerned about?
Whats that got to do with Creo? Do you know what Creo do?
I have just heard on the BBc news that endoscopy will not be needed. You will just swallow a pill with a mini camera inside. Startling.
Having watched for years I’ve finally bought in. They’re overpriced but have decent potential.
Trading statement at last! Terrific to see the potential confirmed, with significant revenue and cash generation kicking in for the first time. Excellent performance given the conditions: solid commercial progress.
Strong regulatory and commercial progress achieved despite worldwide COVID-19 restrictions
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that trading for the year ended 31 December 2020 was marginally ahead of management expectations, with revenue for the year ended 31 December 2020 increasing to over £9m (2019: £0.01m). The Company had a net cash position at 31 December 2020 in excess of £45m.
Encouraging- from the renishaw half year results ...non covid activity starting again - as it must.
“We have seen growth in our neurological product line and good growth in our spectroscopy product line which has seen a recovery in Raman spectrometer investment across all our regions, plus increasing adoption of the Virsa™ Raman Analyzer which was launched during FY 2019/20. We are also seeing that those surgeries and procedures that were delayed due to the pandemic have started to be rescheduled.“
Don't think it's been announced, but there may be a trading update the end of next week - last year there was one on 30th Jan
Craig Gulliford, Chief Executive Officer of Creo, commented:
"We are delighted to receive FDA clearance for the MicroBlate™ Flex device and we remain focussed on completing our programme of regulatory clearances for the full suite of advanced energy surgery products for the flexible endoscopy market. We expect to see further first clinical use of our products in various markets and we look forward to utilising our enhanced global sales and marketing capability to drive commercialisation of our range."
Hopefully, many more patients will be helped and protected by successful use of this ingenious device. Regardless of finances, this is a minor medical breakthrough to celebrate.
Company should be on a steady march now, with proven products ready to go and a widening distribution network.
With "no sales forecasts", the appropriate valuation is surely unknown rather than "premium", it could just as well be undervalued. with cutting edge (!) products the entire world needs.
Interesting company, but a premium valuation at present as we have no sales forecasts... One to watch for sure.